CoChat
Sign Up
Cited by 23

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

iPSC-derived PSEN2 (N141I) astrocytes and microglia exhibit a primed inflammatory phenotype

Sullivan, Michael A., Lane, Samuel D., McKenzie, André D. J., Ball, Sarah R., Sunde, Margaret, Neely, G. Gregory, Moreno, Cesar L., Maximova, Alexandra, Werry, Eryn L., Kassiou, Michael·2024·Journal of Neuroinflammation
DOI 10.1186/s12974-023-02951-2PMC PMC10765839

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Background: Widescale evidence points to the involvement of glia and immune pathways in the progression of Alzheimer’s disease (AD). AD-associated iPSC-derived glial cells show a diverse range of AD-related phenotypic states encompassing cytokine/chemokine release, phagocytosis and morphological profiles, but to date studies are limited to cells derived from PSEN1, APOE and APP mutations or sporadic patients. The aim of the current study was to successfully differentiate iPSC-derived microglia and astrocytes from patients harbouring an AD-causative PSEN2 (N141I) mutation and characterise the inflammatory and morphological profile of these cells. Methods: iPSCs from three healthy control individuals and three familial AD patients harbouring a heterozygous PSEN2 (N141I) mutation were used to derive astrocytes and microglia-like cells and cell identity and morphology were characterised through immunofluorescent microscopy. Cellular characterisation involved the stimulation of these cells by LPS and Aβ 42 and analysis of cytokine/chemokine release was conducted through ELISAs and multi-cytokine arrays. The phagocytic capacity of these cells was then indexed by the uptake of fluorescently-labelled fibrillar Aβ 42 . Results: AD-derived astrocytes and microglia-like cells exhibited an atrophied and less complex morphological appearance than healthy controls. AD-derived astrocytes showed increased basal expression of GFAP, S100β and increased secretion and phagocytosis of Aβ 42 while AD-derived microglia-like cells showed decreased IL-8 secretion compared to healthy controls. Upon immunological challenge AD-derived astrocytes and microglia-like cells showed exaggerated secretion of the pro-inflammatory IL-6, CXCL1, ICAM-1 and IL-8 from astrocytes and IL-18 and MIF from microglia. Conclusion: Our study showed, for the first time, the differentiation and characterisation of iPSC-derived astrocytes and microglia-like cells harbouring a PSEN2 (N141I) mutation. PSEN2 (N141I)-mutant astrocytes and microglia-like cells presented with a ‘primed’ phenotype characterised by reduced morphological complexity, exaggerated pro-inflammatory cytokine secretion and altered Aβ 42 production and phagocytosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-023-02951-2

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 A Overview of differentiation timeline for iPSC-derived NPCs showing representative brightfield images on the last day of each stage. Representative immunofluorescence images of iPSC-derived NPCs from healthy control lines and familial AD lines harbouring a PSEN2 (N141I) mutation. The cells were stained for B the neural progenitor markers Pax-6 (red) and Nestin (green), C a pluripotency marker Oct3 (green) and all nuclei were counterstained with DAPI (blue). Insert shows higher magnification. All scale bars = 50 μm. The percentage of iPSC-derived NPCs positive for D Pax6 and E nestin, with each bar displaying the mean ± SD of three cell lines with n ≥ 2 independent experiments per line. Immunofluorescence staining of all iPSC and astrocyte cell lines can be found in Additional file 1: Fig. S2, S3 and S4
Fig. 1 A Overview of differentiation timeline for iPSC-derived NPCs showing representative brightfield images on the last day of each stage. Representative immunofluorescence images of iPSC-derived NPCs from healthy control lines and familial AD lines harbouring a PSEN2 (N141I) mutation. The cells were stained for B the neural progenitor markers Pax-6 (red) and Nestin (green), C a pluripotency marker Oct3 (green) and all nuclei were counterstained with DAPI (blue). Insert shows higher magnification. All scale bars = 50 μm. The percentage of iPSC-derived NPCs positive for D Pax6 and E nestin, with each bar displaying the mean ± SD of three cell lines with n ≥ 2 independent experiments per line. Immunofluorescence staining of all iPSC and astrocyte cell lines can be found in Additional file 1: Fig. S2, S3 and S4CC BY · PubMed Central
Fig. 2 A Representative immunofluorescence images of iPSC-derived astrocytes from healthy control lines and familial AD lines harbouring a PSEN2 (N141I) mutation. The cells were stained for astrocyte markers GFAP (red) and S100β (green) and B the NPC marker nestin (green) and all nuclei were counterstained with DAPI (blue). Insert shows higher magnification. All scale bars = 50 μm. The percentage of iPSC-derived astrocytes positive for C) GFAP and D S100β. Mean fluorescence intensity of E GFAP and F S100β per astrocyte. An unpaired t-test was used to test whether there were statistically significant differences between the means of AD-derived and healthy control astrocytes. Each bar displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line (**p < 0.01). Immunofluorescence staining of all cell lines can be found in Additional file 1: Fig. S4
Fig. 2 A Representative immunofluorescence images of iPSC-derived astrocytes from healthy control lines and familial AD lines harbouring a PSEN2 (N141I) mutation. The cells were stained for astrocyte markers GFAP (red) and S100β (green) and B the NPC marker nestin (green) and all nuclei were counterstained with DAPI (blue). Insert shows higher magnification. All scale bars = 50 μm. The percentage of iPSC-derived astrocytes positive for C) GFAP and D S100β. Mean fluorescence intensity of E GFAP and F S100β per astrocyte. An unpaired t-test was used to test whether there were statistically significant differences between the means of AD-derived and healthy control astrocytes. Each bar displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line (**p < 0.01). Immunofluorescence staining of all cell lines can be found in Additional file 1: Fig. S4CC BY · PubMed Central
Fig. 3 A Overview of differentiation timeline for iPSC-derived microglia-like cells showing representative brightfield images on the last day of each stage. B Representative immunofluorescence images of iPSC-derived microglia from healthy control lines and familial AD lines harbouring a PSEN2 (N141I) mutation. The cells were stained for microglial markers IBA1 (red), TREM2 (green) and all nuclei were counterstained with DAPI (blue). Insert shows higher magnification. All scale bars = 50 μm. The percentage of iPSC-derived microglia-like cells positive for C IBA1 and D TREM2. Mean fluorescence intensity of E IBA1 and F TREM2 per cell. An unpaired t-test was used to test whether there were statistically significant differences between the means of AD-derived and healthy control microglia. Each bar displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line (**p < 0.01). Immunofluorescence staining of all cell lines can be found in Additional file 1: Fig. S6
Fig. 3 A Overview of differentiation timeline for iPSC-derived microglia-like cells showing representative brightfield images on the last day of each stage. B Representative immunofluorescence images of iPSC-derived microglia from healthy control lines and familial AD lines harbouring a PSEN2 (N141I) mutation. The cells were stained for microglial markers IBA1 (red), TREM2 (green) and all nuclei were counterstained with DAPI (blue). Insert shows higher magnification. All scale bars = 50 μm. The percentage of iPSC-derived microglia-like cells positive for C IBA1 and D TREM2. Mean fluorescence intensity of E IBA1 and F TREM2 per cell. An unpaired t-test was used to test whether there were statistically significant differences between the means of AD-derived and healthy control microglia. Each bar displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line (**p < 0.01). Immunofluorescence staining of all cell lines can be found in Additional file 1: Fig. S6CC BY · PubMed Central
Fig. 4 Morphological characterisation of iPSC-derived astrocytes from three healthy control and three familial AD lines harbouring a PSEN2 (N141I) mutation. Quantification of A average cell perimeter, B average cell circularity and C average cell volume were determined using GFAP and S100β immunofluorescence and 3D reconstruction within FIJI. D Individual cells were categorised and based on morphological appearance, with representative phenotypes of ‘arborised’, ‘polarised’ and ‘process devoid’ cells illustrated in E. An unpaired t-test (A–C) or two-way ANOVA with a post hoc Dunnett’s test (D) were used to test whether there were statistically significant differences between the means of AD-derived and healthy control astrocytes for each morphological category. The figure displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line (*p < 0.05, **p < 0.01, ***p < 0.001). Scale bar = 50 μm
Fig. 4 Morphological characterisation of iPSC-derived astrocytes from three healthy control and three familial AD lines harbouring a PSEN2 (N141I) mutation. Quantification of A average cell perimeter, B average cell circularity and C average cell volume were determined using GFAP and S100β immunofluorescence and 3D reconstruction within FIJI. D Individual cells were categorised and based on morphological appearance, with representative phenotypes of ‘arborised’, ‘polarised’ and ‘process devoid’ cells illustrated in E. An unpaired t-test (A–C) or two-way ANOVA with a post hoc Dunnett’s test (D) were used to test whether there were statistically significant differences between the means of AD-derived and healthy control astrocytes for each morphological category. The figure displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line (*p < 0.05, **p < 0.01, ***p < 0.001). Scale bar = 50 μmCC BY · PubMed Central
Fig. 5 A An example of the processing of an immunofluorescence image of iPSC-derived microglia-like cells stained for IBA1 (red), the result of image processing is shown in binary and was followed by skeletonisation (green). An overlay of the original IBA1 image (red) and skeleton (green) is shown for comparison. Automated analysis of the mean number of B junctions, C branches, D endpoints and E longest branch length per cell. An unpaired t-test was used to test whether there were statistically significant differences between the means of AD-derived and healthy control microglia-like cells. The figure displays the mean ± SD of three cell lines with n = 2 independent experiments per line (*p < 0.05)
Fig. 5 A An example of the processing of an immunofluorescence image of iPSC-derived microglia-like cells stained for IBA1 (red), the result of image processing is shown in binary and was followed by skeletonisation (green). An overlay of the original IBA1 image (red) and skeleton (green) is shown for comparison. Automated analysis of the mean number of B junctions, C branches, D endpoints and E longest branch length per cell. An unpaired t-test was used to test whether there were statistically significant differences between the means of AD-derived and healthy control microglia-like cells. The figure displays the mean ± SD of three cell lines with n = 2 independent experiments per line (*p < 0.05)CC BY · PubMed Central
Fig. 6 Concentration of IL-6 secreted from healthy control or AD-derived astrocytes A basally and after exposure to 10 or 50 μg/mL LPS for 24 h. B Data from part A represented as individual cell lines. Cell lines were re-categorised based on their APOE ε3/ε3 (Ctrl-06, Ctrl-71 and fAD-08) or APOE ε3/ε4 (Ctrl-88, fAD-948 and fAD-950) genotype and shows the concentration of IL-6 secretion C basally and after exposure to 10 or 50 μg/mL LPS for 24 h. A two-way ANOVA with multiple comparisons and post hoc Dunnett’s test was used to test whether there were statistically significant differences between the means of AD-derived and healthy control astrocytes or APOE ε3/ε3 and APOE ε3/ε4 astrocytes (***p < 0.001). Statistical tests were not conducted for figure B. Figures A and C display the mean ± SD of three cell lines with n ≥ 2 independent experiments per line, B display the mean ± SD of n ≥ 2 independent experiments per line
Fig. 6 Concentration of IL-6 secreted from healthy control or AD-derived astrocytes A basally and after exposure to 10 or 50 μg/mL LPS for 24 h. B Data from part A represented as individual cell lines. Cell lines were re-categorised based on their APOE ε3/ε3 (Ctrl-06, Ctrl-71 and fAD-08) or APOE ε3/ε4 (Ctrl-88, fAD-948 and fAD-950) genotype and shows the concentration of IL-6 secretion C basally and after exposure to 10 or 50 μg/mL LPS for 24 h. A two-way ANOVA with multiple comparisons and post hoc Dunnett’s test was used to test whether there were statistically significant differences between the means of AD-derived and healthy control astrocytes or APOE ε3/ε3 and APOE ε3/ε4 astrocytes (***p < 0.001). Statistical tests were not conducted for figure B. Figures A and C display the mean ± SD of three cell lines with n ≥ 2 independent experiments per line, B display the mean ± SD of n ≥ 2 independent experiments per lineCC BY · PubMed Central
Fig. 7 The concentration of A secreted IL-6 and B viability of AD-derived and healthy control astrocytes after stimulation with initially monomeric 0, 5 or 10 μM Aβ42 for 24 h. Cell lines were re-categorised based on their APOE ε3/ε3 (Ctrl-06, Ctrl-71 and fAD-08) or APOE ε3/ε4 (Ctrl-88, fAD-948 and fAD-950) genotype and shows the concentration of C secreted IL-6 and D viability after exposure to 0, 5 or 10 μM Aβ42 for 24 h. The figure displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line. A two-way ANOVA with post hoc Dunnett’s test was used to test whether there were statistically significant differences between mean of AD-derived and healthy control astrocytes and APOE ε3/ε3 and APOE ε3/ε4 astrocytes (**p < 0.01, ***p < 0.001)
Fig. 7 The concentration of A secreted IL-6 and B viability of AD-derived and healthy control astrocytes after stimulation with initially monomeric 0, 5 or 10 μM Aβ42 for 24 h. Cell lines were re-categorised based on their APOE ε3/ε3 (Ctrl-06, Ctrl-71 and fAD-08) or APOE ε3/ε4 (Ctrl-88, fAD-948 and fAD-950) genotype and shows the concentration of C secreted IL-6 and D viability after exposure to 0, 5 or 10 μM Aβ42 for 24 h. The figure displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line. A two-way ANOVA with post hoc Dunnett’s test was used to test whether there were statistically significant differences between mean of AD-derived and healthy control astrocytes and APOE ε3/ε3 and APOE ε3/ε4 astrocytes (**p < 0.01, ***p < 0.001)CC BY · PubMed Central
Fig. 8 Multi-cytokine array of AD-derived or healthy iPSC-derived astrocytes A basally and B after 24 h exposure to 10 μM Aβ42 and iPSC-derived microglia-like cells C basally and D after 24 h exposure to 10 μM Aβ42. The figure displays the mean ± SD of three cell lines with the average of two experimental duplicates per line. Multiple unpaired, non-parametric Mann–Whitney t-tests adjusting for a 5% false discovery rate were used to test whether there were statistically significant differences between mean cytokine/chemokine release of AD-derived and healthy control astrocytes and microglia-like cells (*p < 0.05, **p < 0.01). Cytokines/chemokines with mean pixel density under 10% of the maximum in both basal and Aβ42-stimulated conditions were considered background and are not shown, full cytokine array is shown in Additional file 1: Figs. S7 and S8
Fig. 8 Multi-cytokine array of AD-derived or healthy iPSC-derived astrocytes A basally and B after 24 h exposure to 10 μM Aβ42 and iPSC-derived microglia-like cells C basally and D after 24 h exposure to 10 μM Aβ42. The figure displays the mean ± SD of three cell lines with the average of two experimental duplicates per line. Multiple unpaired, non-parametric Mann–Whitney t-tests adjusting for a 5% false discovery rate were used to test whether there were statistically significant differences between mean cytokine/chemokine release of AD-derived and healthy control astrocytes and microglia-like cells (*p < 0.05, **p < 0.01). Cytokines/chemokines with mean pixel density under 10% of the maximum in both basal and Aβ42-stimulated conditions were considered background and are not shown, full cytokine array is shown in Additional file 1: Figs. S7 and S8CC BY · PubMed Central
Fig. 9 Concentrations of A Aβ42, B Aβ40, C the ratio of Aβ42:40 and D total Aβ protein quantified from iPSC-derived astrocyte supernatants 72 h after plating. Secreted Aβ concentrations were measured using a highly sensitive ELISA and normalised to total protein concentration determined by BCA. The figure displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line. An unpaired t-test was used to test whether there were statistically significant differences between mean of AD-derived and healthy control astrocytes (*p < 0.05)
Fig. 9 Concentrations of A Aβ42, B Aβ40, C the ratio of Aβ42:40 and D total Aβ protein quantified from iPSC-derived astrocyte supernatants 72 h after plating. Secreted Aβ concentrations were measured using a highly sensitive ELISA and normalised to total protein concentration determined by BCA. The figure displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line. An unpaired t-test was used to test whether there were statistically significant differences between mean of AD-derived and healthy control astrocytes (*p < 0.05)CC BY · PubMed Central
Fig. 10 AD-derived and healthy A iPSC-derived astrocytes and B iPSC-derived microglia-like cells were exposed to 488-fluorescent-Aβ42 fibrils for 2 h and phagocytosis was quantified through average fluorescent intensity per cell. The figure shows the percentage of B iPSC-derived astrocytes and D iPSC-derived microglia-like cells which show any uptake of Aβ42. The figure displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line. An unpaired t-test was used to test whether there were statistically significant differences between mean of AD-derived and healthy control astrocytes (*p < 0.05). Representative overlay of brightfield and fluorescent images of E iPSC-derived astrocytes and F iPSC-derived microglia-like cells, fluorescent Aβ42 fibrils shown in green, scale bar = 50 μm
Fig. 10 AD-derived and healthy A iPSC-derived astrocytes and B iPSC-derived microglia-like cells were exposed to 488-fluorescent-Aβ42 fibrils for 2 h and phagocytosis was quantified through average fluorescent intensity per cell. The figure shows the percentage of B iPSC-derived astrocytes and D iPSC-derived microglia-like cells which show any uptake of Aβ42. The figure displays the mean ± SD of three cell lines with n ≥ 2 independent experiments per line. An unpaired t-test was used to test whether there were statistically significant differences between mean of AD-derived and healthy control astrocytes (*p < 0.05). Representative overlay of brightfield and fluorescent images of E iPSC-derived astrocytes and F iPSC-derived microglia-like cells, fluorescent Aβ42 fibrils shown in green, scale bar = 50 μmCC BY · PubMed Central
Fig. 11 Graphical representation and summary of morphological and immunological features of iPSC-derived microglia-like cells (top) and astrocytes (bottom) from healthy (left) and PSEN2 (N141I)-mutant fAD (right) origin. Created with Biorender.com
Fig. 11 Graphical representation and summary of morphological and immunological features of iPSC-derived microglia-like cells (top) and astrocytes (bottom) from healthy (left) and PSEN2 (N141I)-mutant fAD (right) origin. Created with Biorender.comCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 76

  1. Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer’s disease. Hum Mol Genet. 2009;18(R2):R137–45. · DOI · Paper page
  2. D’Avanzo C, Aronson J, Kim YH, Choi SH, Tanzi RE, Kim DY. Alzheimer’s in 3D culture: challenges and perspectives. BioEssays. 2015;37(10):1139–48. · DOI · Paper page
  3. De Jonghe C, Esselens C, Kumar-Singh S, Craessaerts K, Serneels S, Checler F, et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001;10(16):1665–71. · DOI · Paper page
  4. Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741–66. · DOI · Paper page
  5. Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, et al. Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133(Pt 4):1143–54. · DOI
  6. Ortiz-Virumbrales M, Moreno CL, Kruglikov I, Marazuela P, Sproul A, Jacob S, et al. CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer’s PSEN2 N141I neurons. Acta Neuropathol Commun. 2017;5(1):1–20. · DOI
  7. Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120(4):545–55. · DOI · Paper page
  8. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45(12):1452–8. · DOI · Paper page
  9. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358(9280):461–7. · DOI · Paper page
  10. Funato H, Yoshimura M, Yamazaki T, Saido TC, Ito Y, Yokofujita J, et al. Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am J Pathol. 1998;152(4):983–92.
  11. Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi EJ, Moeton M, et al. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer’s disease. Neurobiol Aging. 2014;35(3):492–510. · DOI
  12. Nagele RG, D’Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003;971(2):197–209. · DOI · Paper page
  13. Senitz D, Reichenbach A, Smith TG Jr. Surface complexity of human neocortical astrocytic cells: changes with development, aging, and dementia. J Hirnforsch. 1995;36(4):531–7.
  14. Dandrea MR, Reiser PA, Gumula NA, Hertzog BM, Andrade-Gordon P. Application of triple immunohistochemistry to characterize amyloid plaque-associated inflammation in brains with Alzheimer’s disease. Biotech Histochem. 2001;76(2):97–106. · DOI
  15. Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psychiatry Clin Neurosci. 1997;51(3):135–8. · DOI · Paper page
  16. Shao Y, Gearing M, Mirra SS. Astrocyte-apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study. J Neuropathol Exp Neurol. 1997;56(4):376–81. · DOI
  17. Camp JG, Badsha F, Florio M, Kanton S, Gerber T, Wilsch-Brauninger M, et al. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. Proc Natl Acad Sci U S A. 2015;112(51):15672–7. · DOI · Paper page
  18. Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, et al. iPSC-derived human microglia-like cells to study neurological diseases. Neuron. 2017;94(2):278-93.e9. · DOI · Paper page
  19. Jones VC, Atkinson-Dell R, Verkhratsky A, Mohamet L. Aberrant iPSC-derived human astrocytes in Alzheimer’s disease. Cell Death Dis. 2017;8(3): e2696. · DOI · Paper page
  20. Konttinen H, Cabral-da-Silva MEC, Ohtonen S, Wojciechowski S, Shakirzyanova A, Caligola S, et al. PSEN1DeltaE9, APPswe, and APOE4 confer disparate phenotypes in human iPSC-derived microglia. Stem Cell Rep. 2019;13(4):669–83. · DOI · Paper page
  21. Konttinen H, Gureviciene I, Oksanen M, Grubman A, Loppi S, Huuskonen MT, et al. PPARbeta/delta-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1DeltaE9 astrocytes. Glia. 2019;67(1):146–59. · DOI
  22. Guttikonda SR, Sikkema L, Tchieu J, Saurat N, Walsh RM, Harschnitz O, et al. Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in Alzheimer’s disease. Nat Neurosci. 2021;24(3):343–54. · DOI
  23. Xu M, Zhang L, Liu G, Jiang N, Zhou W, Zhang Y. Pathological changes in Alzheimer’s disease analyzed using induced pluripotent stem cell-derived human microglia-like cells. J Alzheimers Dis. 2019;67(1):357–68. · DOI · Paper page
  24. Walsh DM, Thulin E, Minogue AM, Gustavsson N, Pang E, Teplow DB, et al. A facile method for expression and purification of the Alzheimer’s disease-associated amyloid beta-peptide. FEBS J. 2009;276(5):1266–81. · DOI
  25. Tian C, Liu Q, Ma K, Wang Y, Chen Q, Ambroz R, et al. Characterization of induced neural progenitors from skin fibroblasts by a novel combination of defined factors. Sci Rep. 2013;3:1345. · DOI
  26. Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957–67. · DOI · Paper page
  27. Franco-Bocanegra DK, Gourari Y, McAuley C, Chatelet DS, Johnston DA, Nicoll JAR, et al. Microglial morphology in Alzheimer’s disease and after Abeta immunotherapy. Sci Rep. 2021;11(1):15955. · DOI
  28. Davies DS, Ma J, Jegathees T, Goldsbury C. Microglia show altered morphology and reduced arborization in human brain during aging and Alzheimer’s disease. Brain Pathol. 2017;27(6):795–808. · DOI · Paper page
  29. Young K, Morrison H. Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using imageJ. J Vis Exp. 2018;136:e57648.
  30. Brandenburg LO, Konrad M, Wruck CJ, Koch T, Lucius R, Pufe T. Functional and physical interactions between formyl-peptide-receptors and scavenger receptor MARCO and their involvement in amyloid beta 1–42-induced signal transduction in glial cells. J Neurochem. 2010;113(3):749–60. · DOI
  31. Xu X, Lei Y, Luo J, Wang J, Zhang S, Yang XJ, et al. Prevention of beta-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events. Stem Cell Res. 2013;10(2):213–27. · DOI
  32. Ferreira A, Sinjoanu RC, Nicholson A, Kleinschmidt S. Abeta toxicity in primary cultured neurons. Methods Mol Biol. 2011;670:141–53. · DOI
  33. Veeraraghavalu K, Zhang C, Zhang X, Tanzi RE, Sisodia SS. Age-dependent, non-cell-autonomous deposition of amyloid from synthesis of beta-amyloid by cells other than excitatory neurons. J Neurosci. 2014;34(10):3668–73. · DOI
  34. Carpenter AF, Carpenter PW, Markesbery WR. Morphometric analysis of microglia in Alzheimer’s disease. J Neuropathol Exp Neurol. 1993;52(6):601–8. · DOI · Paper page
  35. Beauquis J, Pavia P, Pomilio C, Vinuesa A, Podlutskaya N, Galvan V, et al. Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer’s disease. Exp Neurol. 2013;239:28–37. · DOI · Paper page
  36. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s disease. Glia. 2010;58(7):831–8. · DOI · Paper page
  37. Escartin C, Guillemaud O, Carrillo-de Sauvage MA. Questions and (some) answers on reactive astrocytes. Glia. 2019;67(12):2221–47. · DOI · Paper page
  38. Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging. 2010;31(4):578–90. · DOI · Paper page
  39. Kashon ML, Ross GW, O'Callaghan JP, Miller DB, Petrovitch H, Burchfiel CM, et al. Associations of cortical astrogliosis with cognitive performance and dementia status. J Alzheimers Dis. 2004;6(6):595–604; discussion 73–81. · DOI
  40. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86(19):7611–5. · DOI · Paper page
  41. Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer’s disease. J Neuropathol Exp Neurol. 1996;55(3):273–9. · DOI
  42. Sheng JG, Mrak RE, Griffin WS. S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J Neurosci Res. 1994;39(4):398–404. · DOI
  43. Marshak DR, Pesce SA, Stanley LC, Griffin WS. Increased S100 beta neurotrophic activity in Alzheimer’s disease temporal lobe. Neurobiol Aging. 1992;13(1):1–7. · DOI
  44. Brozzi F, Arcuri C, Giambanco I, Donato R. S100B protein regulates astrocyte shape and migration via interaction with Src kinase: implications for astrocyte development, activation and tumor growth. J Biol Chem. 2009;284(13):8797–811. · DOI
  45. Torres-Platas SG, Comeau S, Rachalski A, Bo GD, Cruceanu C, Turecki G, et al. Morphometric characterization of microglial phenotypes in human cerebral cortex. J Neuroinflammation. 2014;11:12. · DOI
  46. Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35:441–68. · DOI · Paper page
  47. Salobrar-Garcia E, Rodrigues-Neves AC, Ramirez AI, de Hoz R, Fernandez-Albarral JA, Lopez-Cuenca I, et al. Microglial activation in the retina of a triple-transgenic Alzheimer’s disease mouse model (3xTg-AD). Int J Mol Sci. 2020;21(3):816. · DOI
  48. Baron R, Babcock AA, Nemirovsky A, Finsen B, Monsonego A. Accelerated microglial pathology is associated with Abeta plaques in mouse models of Alzheimer’s disease. Aging Cell. 2014;13(4):584–95. · DOI · Paper page
  49. Leyh J, Paeschke S, Mages B, Michalski D, Nowicki M, Bechmann I, et al. Classification of Microglial Morphological Phenotypes Using Machine Learning. Front Cell Neurosci. 2021;15: 701673. · DOI
  50. Nam H, Lee Y, Kim B, Lee JW, Hwang S, An HK, et al. Presenilin 2 N141I mutation induces hyperactive immune response through the epigenetic repression of REV-ERBalpha. Nat Commun. 2022;13(1):1972. · DOI
  51. Fung S, Smith CL, Prater KE, Case A, Green K, Osnis L, et al. Early-onset familial Alzheimer disease variant PSEN2 N141I heterozygosity is associated with altered microglia phenotype. J Alzheimers Dis. 2020;77(2):675–88. · DOI
  52. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358–72. · DOI · Paper page
  53. Grehan S, Tse E, Taylor JM. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J Neurosci. 2001;21(3):812–22. · DOI · Paper page
  54. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–18. · DOI · Paper page
  55. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3. · DOI · Paper page
  56. den Hartigh LJ, Altman R, Hutchinson R, Petrlova J, Budamagunta MS, Tetali SD, et al. Postprandial apoE isoform and conformational changes associated with VLDL lipolysis products modulate monocyte inflammation. PLoS ONE. 2012;7(11): e50513. · DOI
  57. Hatters DM, Budamagunta MS, Voss JC, Weisgraber KH. Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms. J Biol Chem. 2005;280(40):34288–95. · DOI · Paper page
  58. Maezawa I, Maeda N, Montine TJ, Montine KS. Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice. J Neuroinflammation. 2006;3:10. · DOI
  59. Ophir G, Meilin S, Efrati M, Chapman J, Karussis D, Roses A, et al. Human apoE3 but not apoE4 rescues impaired astrocyte activation in apoE null mice. Neurobiol Dis. 2003;12(1):56–64. · DOI
  60. Fraga VG, Magalhaes CA, Loures CMG, de Souza LC, Guimaraes HC, Zauli DAG, et al. Inflammatory and pro-resolving mediators in frontotemporal dementia and Alzheimer’s disease. Neuroscience. 2019;421:123–35. · DOI
  61. Ehrlich LC, Hu S, Sheng WS, Sutton RL, Rockswold GL, Peterson PK, et al. Cytokine regulation of human microglial cell IL-8 production. J Immunol. 1998;160(4):1944–8. · DOI
  62. Araujo DM, Cotman CW. Trophic effects of interleukin-4, -7 and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors. Brain Res. 1993;600(1):49–55. · DOI
  63. Verbeek MM, Otte-Holler I, Westphal JR, Wesseling P, Ruiter DJ, de Waal RM. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer’s disease. Am J Pathol. 1994;144(1):104–16.
  64. Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. Microglial cells around amyloid plaques in Alzheimer’s disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett. 1989;101(3):288–92. · DOI
  65. Noe CR, Noe-Letschnig M, Handschuh P, Noe CA, Lanzenberger R. Dysfunction of the Blood-Brain Barrier-A Key Step in Neurodegeneration and Dementia. Front Aging Neurosci. 2020;12:185. · DOI
  66. Nielsen HM, Londos E, Minthon L, Janciauskiene SM. Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis. 2007;26(1):27–35. · DOI · Paper page
  67. Clark PR, Manes TD, Pober JS, Kluger MS. Increased ICAM-1 expression causes endothelial cell leakiness, cytoskeletal reorganization and junctional alterations. J Invest Dermatol. 2007;127(4):762–74. · DOI
  68. Rentzos M, Michalopoulou M, Nikolaou C, Cambouri C, Rombos A, Dimitrakopoulos A, et al. The role of soluble intercellular adhesion molecules in neurodegenerative disorders. J Neurol Sci. 2005;228(2):129–35. · DOI · Paper page
  69. Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91(9):e867–77. · DOI · Paper page
  70. Perez-Nievas BG, Johnson L, Beltran-Lobo P, Hughes MM, Gammallieri L, Tarsitano F, et al. Astrocytic C-X-C motif chemokine ligand-1 mediates beta-amyloid-induced synaptotoxicity. J Neuroinflammation. 2021;18(1):306. · DOI
  71. Prinz M, Hanisch UK. Murine microglial cells produce and respond to interleukin-18. J Neurochem. 1999;72(5):2215–8. · DOI
  72. Nasiri E, Sankowski R, Dietrich H, Oikonomidi A, Huerta PT, Popp J, et al. Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer’s disease. Mol Med. 2020;26(1):34. · DOI · Paper page
  73. Ojala J, Alafuzoff I, Herukka SK, van Groen T, Tanila H, Pirttila T. Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients. Neurobiol Aging. 2009;30(2):198–209. · DOI · Paper page
  74. Monaco G, van Dam S, Casal Novo Ribeiro JL, Larbi A, de Magalhaes JP. A comparison of human and mouse gene co-expression networks reveals conservation and divergence at the tissue, pathway and disease levels. BMC Evol Biol. 2015;15:259. · DOI
  75. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330(6012):1774. · DOI · Paper page
  76. Reich M, Paris I, Ebeling M, Dahm N, Schweitzer C, Reinhardt D, et al. Alzheimer’s risk gene TREM2 determines functional properties of new type of human iPSC-derived microglia. Front Immunol. 2020;11: 617860. · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Sullivan, M. A., Lane, S. D., McKenzie, A. D. J., Ball, S. R., Sunde, M., Neely, G. G., Moreno, C. L., Maximova, A., Werry, E. L., & Kassiou, M.
Venue
Journal of Neuroinflammation
Publisher
Springer Science and Business Media LLC
Published
2024-01-04
Volume
21
Issue
1
ISSN
1742-2094
DOI
10.1186/s12974-023-02951-2
PMC
PMC10765839
Cited by
23
References
20
Language
en
Licence
Funders
National Health and Medical Research Council (Program Grant (APP1132524), Principal Research Fellowship (APP1154692))

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review